Research ExplorerPublicationsEinsatz von Neuen oralen Antikoagulanzien (NOAK) bei onkolog...

Einsatz von Neuen oralen Antikoagulanzien (NOAK) bei onkologischen Patienten

Standard

Einsatz von Neuen oralen Antikoagulanzien (NOAK) bei onkologischen Patienten. / Trappe, Ralf Ulrich; Sinn, Marianne; Riess, Hanno.

In: DEUT MED WOCHENSCHR, Vol. 141, No. 20, 09.2016, p. 1446-1450.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Trappe, RU, Sinn, M & Riess, H 2016, 'Einsatz von Neuen oralen Antikoagulanzien (NOAK) bei onkologischen Patienten', DEUT MED WOCHENSCHR, vol. 141, no. 20, pp. 1446-1450. https://doi.org/10.1055/s-0042-112085

APA

Trappe, R. U., Sinn, M., & Riess, H. (2016). Einsatz von Neuen oralen Antikoagulanzien (NOAK) bei onkologischen Patienten. DEUT MED WOCHENSCHR, 141(20), 1446-1450. https://doi.org/10.1055/s-0042-112085

Vancouver

Trappe RU, Sinn M, Riess H. Einsatz von Neuen oralen Antikoagulanzien (NOAK) bei onkologischen Patienten. DEUT MED WOCHENSCHR. 2016 Sep;141(20):1446-1450. https://doi.org/10.1055/s-0042-112085

Bibtex

@article{6c2ec28940454e9bb6d9dc1ed583fe85,
title = "Einsatz von Neuen oralen Antikoagulanzien (NOAK) bei onkologischen Patienten",
abstract = "There is only limited data for the use of direct oral anticoagulants (DOACs) in tumor patients and no data from prospective randomised trials comparing DOACs to the current standard care: low molecular weight heparine (LMWH). Therefore, DOACs must be used with caution and should be restricted to tumor patients with (1) contraindications for LMWH (e.g. HIT II, phobia of syringe) or (2) to the situations of prolonged anticoagulation after initial therapy with LMWH. Cancer-associated disorders as well as side effects of chemotherapy as nausea and emesis have to be considered as well as potential substance-specific interactions. Data of future clinical trials in prophylaxis and treatment of venous thrombembolism in tumor patients will help to define the role of DOACs in this special patient cohort.",
keywords = "Administration, Oral, Anticoagulants/administration & dosage, Antineoplastic Agents/administration & dosage, Drug Interactions, Evidence-Based Medicine, Humans, Neoplasms/complications, Risk Factors, Thromboembolism/etiology, Treatment Outcome",
author = "Trappe, {Ralf Ulrich} and Marianne Sinn and Hanno Riess",
note = "{\textcopyright} Georg Thieme Verlag KG Stuttgart · New York.",
year = "2016",
month = sep,
doi = "10.1055/s-0042-112085",
language = "Deutsch",
volume = "141",
pages = "1446--1450",
journal = "DEUT MED WOCHENSCHR",
issn = "0012-0472",
publisher = "Georg Thieme Verlag KG",
number = "20",

}

RIS

TY - JOUR

T1 - Einsatz von Neuen oralen Antikoagulanzien (NOAK) bei onkologischen Patienten

AU - Trappe, Ralf Ulrich

AU - Sinn, Marianne

AU - Riess, Hanno

N1 - © Georg Thieme Verlag KG Stuttgart · New York.

PY - 2016/9

Y1 - 2016/9

N2 - There is only limited data for the use of direct oral anticoagulants (DOACs) in tumor patients and no data from prospective randomised trials comparing DOACs to the current standard care: low molecular weight heparine (LMWH). Therefore, DOACs must be used with caution and should be restricted to tumor patients with (1) contraindications for LMWH (e.g. HIT II, phobia of syringe) or (2) to the situations of prolonged anticoagulation after initial therapy with LMWH. Cancer-associated disorders as well as side effects of chemotherapy as nausea and emesis have to be considered as well as potential substance-specific interactions. Data of future clinical trials in prophylaxis and treatment of venous thrombembolism in tumor patients will help to define the role of DOACs in this special patient cohort.

AB - There is only limited data for the use of direct oral anticoagulants (DOACs) in tumor patients and no data from prospective randomised trials comparing DOACs to the current standard care: low molecular weight heparine (LMWH). Therefore, DOACs must be used with caution and should be restricted to tumor patients with (1) contraindications for LMWH (e.g. HIT II, phobia of syringe) or (2) to the situations of prolonged anticoagulation after initial therapy with LMWH. Cancer-associated disorders as well as side effects of chemotherapy as nausea and emesis have to be considered as well as potential substance-specific interactions. Data of future clinical trials in prophylaxis and treatment of venous thrombembolism in tumor patients will help to define the role of DOACs in this special patient cohort.

KW - Administration, Oral

KW - Anticoagulants/administration & dosage

KW - Antineoplastic Agents/administration & dosage

KW - Drug Interactions

KW - Evidence-Based Medicine

KW - Humans

KW - Neoplasms/complications

KW - Risk Factors

KW - Thromboembolism/etiology

KW - Treatment Outcome

U2 - 10.1055/s-0042-112085

DO - 10.1055/s-0042-112085

M3 - SCORING: Review

C2 - 27701688

VL - 141

SP - 1446

EP - 1450

JO - DEUT MED WOCHENSCHR

JF - DEUT MED WOCHENSCHR

SN - 0012-0472

IS - 20

ER -